Latest Us Army News

Environmental Clean Technologies (ASX: ECT) has submitted detailed data to the US EPA showcasing its Rapid Electrothermal Mineralisation (REM) technology's ability to destroy PFAS with over 99% efficacy and full fluorine mass balance, aiming to meet stringent regulatory standards.

Island Pharmaceuticals has won a key regulatory boost as the US FDA granted Orphan Drug Designation to Galidesivir for post-exposure prophylaxis of Marburg virus disease, enhancing its commercial and development prospects.

Environmental Clean Technologies (ASX: ECT) has completed a pilot Rapid Electrothermal Mineralisation system that delivers 18 times the power of its lab prototype, enabling additive-free, in-situ PFAS destruction and targeting a field demonstration in H2 2026.

Island Pharmaceuticals is accelerating development of its broad-spectrum antiviral Galidesivir, progressing clinical, regulatory, and manufacturing milestones under the FDA Animal Rule pathway with expanded USAMRIID collaboration and biodefence positioning.

Island Pharmaceuticals has expanded its partnership with USAMRIID to conduct a pivotal Galidesivir dose optimisation study against Marburg virus, targeting topline results in the second half of 2026.

Vitrafy Life Sciences has teamed up with Vitalant Innovation Center to tackle the impending gap in red blood cell cryopreservation technology in the US, aiming to replace soon-to-be-discontinued legacy methods and potentially expand into other blood products.

Vitrafy Life Sciences has achieved a major validation milestone with US Army-backed Phase II results showing its no-wash platelet cryopreservation protocol delivers 94% post-thaw recovery, outperforming existing standards and advancing FDA registration plans.

Electro Optic Systems (ASX: EOS) reported a 13% increase in contract backlog to A$518 million in Q1 2026, driven by multiple major defence orders and the opening of a new Singapore facility. The company’s cash position remains strong despite a $4 million ASIC penalty.

Island Pharmaceuticals has cleared a major regulatory hurdle with the US FDA, confirming a clinical development path for its antiviral Galidesivir under the Animal Rule. Backed by a $9 million capital raise and strategic partnerships, the company is poised for potential US government procurement and biodefence market entry.

Anson Resources has lodged an updated Small Mining Operations notice for its 10,000tpa Green River lithium carbonate plant in Utah, marking the last significant regulatory hurdle before construction. The revised plant layout, backed by a near-complete Pre-feasibility Study, leverages existing infrastructure and private land ownership to enhance project bankability.

Electro Optic Systems (ASX: EOS) wraps up a three-year turnaround, reporting a $459 million order backlog despite a 27% revenue drop. The company expands its counter-drone and space control portfolio with the acquisition of the UK-based Interceptor business and a pending deal for MARSS, a European command-and-control software provider.

Electro Optic Systems Holdings Limited (ASX: EOS) has responded to ASX queries confirming that non-executive director Robert Nicholson’s on-market purchase of shares complied with the company’s trading policy and ASX Listing Rules. The trade occurred prior to the public announcement of significant US defence contracts.